Compare First Trust NASDAQ 100 Technology Index Fund (QTEC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ 100 Technology Index Fund vs Tango Therapeutics Inc. — how do they compare? First Trust NASDAQ 100 Technology Index Fund trades at $303.09 (market cap $4.40B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: First Trust NASDAQ 100 Technology Index Fund is the larger of the two by market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ 100 Technology Index Fund for 40 Days and Tango Therapeutics Inc. for 0 Days on average.
| QTEC | TNGX | |
|---|---|---|
Market Cap | $4.40B | $3.75B |
Volume | 160,706 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $340.28 | $32.90 |
52-Week Low | $207.03 | $7.50 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $324.27, down 0.59% on the day. The technical outlook is bullish based on moving averages, with key support at $321 and resistance at $335. Recent analysis highlights its equal-weighted exposure to the technology sector and better liquidity compared to peers.
The ETF offers broad tech exposure but faces sector-specific volatility risks. Upside potential hinges on technology sector performance, while downside risks include macroeconomic pressures on growth stocks. Investor sentiment remains mixed with a neutral oscillator reading.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
